Explore more publications!

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Byrna Technologies Inc. - BYRN
ImPact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026
Strata Decision Technology Releases 2026 Healthcare Financial Outlook Report, Highlighting Policy Pressures and Renewed Focus on Disciplined Performance
Nobel-Potential Discovery from VectorBuilder Scientists Reveals Fundamental Mechanisms of Development
Car Detailing Service Market Size worth USD 65.49 Billion by 2032, Exclusive Report by Maximize Market Research
Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
Solidion Technology Joins Forces with Hilco Global to Monetize Patent Portfolio
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
TheJembe Launches Multicultural Intelligence Services to Help Brands Navigate a Changing Market
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
 CAHME Announces the Initial Accreditation of the University of Illinois Urbana-Champaign, MHA
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
Aquatics Safety Experts Address the ‘National Distraction Epidemic’ This Summer
ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
Hanmi Reports 2026 First Quarter Results

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions